Evidence map›Paper›PMID 34646805›Full record

ArticleFrontiers in public health2021

Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.

Julia Schiffner, Insa Backhaus, Jens Rimmele, Sören Schulz, Till Möhlenkamp, Julia Maria Klemens, Dorinja Zapf, Werner Solbach, Alexander Mischnik

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. From immune equilibrium to immunodynamics.Frontiers in microbiology · 2022
    Article
  20. Persistent humoral and CD4Frontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Julia SchiffnerCenter for Infection and Inflammation Research, University of Luebeck, Luebeck, Germany.
Insa BackhausMedical Faculty, Centre for Health and Society, University Hospital, Institute of Medical Sociology, Heinrich-Heine-University, Düsseldorf, Germany.
Jens RimmeleHealth Protection Authority, Luebeck, Germany.
Sören SchulzHealth Protection Authority, Luebeck, Germany.
Till MöhlenkampHealth Protection Authority, Luebeck, Germany.
Julia Maria KlemensInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.
Dorinja ZapfInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.
Werner SolbachCenter for Infection and Inflammation Research, University of Luebeck, Luebeck, Germany.
Alexander MischnikHealth Protection Authority, Luebeck, Germany.
Euroimmun Medizinische Labordiagnostika (Germany) · DEDüsseldorf University Hospital · DEGerman Center for Infection Research · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCross-Sectional StudiesHumansImmunity, CellularImmunoglobulin GOutpatientsProspective StudiesAntibodies, ViralImmunoglobulin GCOVID-19IgGIGRAimmunoglobulininterferon-gamma release assaySARS-CoV-2seroprevalence

Identifiers

PMID34646805
PMCPMC8502872
OpenAlexW3175301581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.